Temporal evolution of antiretroviral therapy (2017-2021): analysis of treatment change and its economic impact

• DOI: 10.37201/req/047.2023
• Publication Date: 2023-09-21T05:49:46Z
• Authors: Elena Herranz-Bayo; Herminia Navarro-...; Andrea Pinilla-Rello; Carlos Ignacio Dí...
• Keywords: Discontinuation

To analyze the modifications of antiretroviral therapy (ART) and their economic impact on daily clinical practice.Observational, retrospective study patients who started ART between 01/2017-12/2021 (follow-up until 12/2022). Variables collected: prescribed ART, duration, reason for change, treatment costs.A total 280 initiated therapy. The median durability 1st line was: 19.9 months in 2017 (95%CI 13.9-25.9), 12.2 2018 4.7-19.7), 27.4 2019 6.8-48.1) was not reached years 2020 2021 (p<0.001). Triple with protease inhibitors changed 63.8% (81/127) cases, followed by integrase 52.1% (159/305), while dual (DTG/3TC) only 8.3% (7/84). main cause discontinuation simplification/optimization 47.5% (124/261), adverse effects 21.8% (57/261), being year where at same level as effects. changes resulted an average cost reduction 34.0€ [-391.4 to +431.4] per month patient. stands out these were associated increase mean additional (23.4€ [-358.3 +431.4]).Optimization/simplification accounts almost half reasons TAR that, despite inflection point 2019, each manages exceed previous one, achieving a progressive maintained over time.